Inclisiran: UK to roll out new cholesterol lowering drug from next year
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m139 (Published 13 January 2020) Cite this as: BMJ 2020;368:m139- Gareth Iacobucci
- The BMJ
The UK government is to launch a major clinical trial of the novel cholesterol lowering drug inclisiran later this year and aims to make it available to NHS patients from 2021.
Inclisiran, an investigational treatment taken by injection twice a year, is a cholesterol lowering therapy in the small interfering RNA (siRNA) class. It has not yet been approved by the US Food and Drug Administration or the European Medicines Agency but is expected to be filed for approval later this year as a preventive add-on treatment to statins for patients who already have a cardiovascular disease diagnosis.
Results of a phase III study of inclisiran involving patients who had elevated LDL cholesterol concentrations despite taking the maximum …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.